Form D · Biotechnology
Syntimmune, Inc.
New York, NY · CIK 0001622964
Offering snapshot reported Jun 28, 2017 · SEC filing
- Reported sold
- $18M Offering amount: $50M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 19, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 28, 2017 | Initial | $17,999,998 | No comparison | 3 | SEC filing |
| Oct 24, 2014 | Initial | $8,000,001 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-289606
Source: Form D, filed Jun 28, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Burt Adelman, M.D. | Director |
| Richard Blumberg, M.D. | Director |
| Laurence Blumberg, M.D. | Director, Executive |
| David De Graaf, Ph.D. | Director, Executive |
| Sam Hall | Director |
| Sam Hall, Ph.D. | Director |
| Seth Harrison | Director |
| Seth Harrison, M.D. | Director |
| Aaron Kantoff | Director |
| Geeta Vemuri | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
257 Park Avenue South 15 Th Floor
New York, NY, 10010
New York, NY, 10010